Phathom Pharmaceuticals Inc (NASDAQ: PHAT)’s stock price has gone rise by 9.87 in comparison to its previous close of 5.58, however, the company has experienced a 6.44% increase in its stock price over the last five trading days. globenewswire.com reported 2025-02-24 that FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, March 6, 2025, to report its fourth quarter and full year 2024 financial results and provide a business update.
Is It Worth Investing in Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Right Now?
PHAT has 36-month beta value of 0.63. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PHAT is 38.09M, and currently, short sellers hold a 38.41% ratio of that float. The average trading volume of PHAT on February 26, 2025 was 985.95K shares.
PHAT’s Market Performance
The stock of Phathom Pharmaceuticals Inc (PHAT) has seen a 6.44% increase in the past week, with a -6.54% drop in the past month, and a -35.12% fall in the past quarter. The volatility ratio for the week is 5.92%, and the volatility levels for the past 30 days are at 7.18% for PHAT. The simple moving average for the past 20 days is 5.78% for PHAT’s stock, with a -46.47% simple moving average for the past 200 days.
Analysts’ Opinion of PHAT
Many brokerage firms have already submitted their reports for PHAT stocks, with Cantor Fitzgerald repeating the rating for PHAT by listing it as a “Overweight.” The predicted price for PHAT in the upcoming period, according to Cantor Fitzgerald is $23 based on the research report published on February 14, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see PHAT reach a price target of $24. The rating they have provided for PHAT stocks is “Buy” according to the report published on May 03rd, 2024.
Needham gave a rating of “Buy” to PHAT, setting the target price at $26 in the report published on January 05th of the previous year.
PHAT Trading at -9.30% from the 50-Day Moving Average
After a stumble in the market that brought PHAT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.89% of loss for the given period.
Volatility was left at 7.18%, however, over the last 30 days, the volatility rate increased by 5.92%, as shares sank -3.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.05% lower at present.
During the last 5 trading sessions, PHAT rose by +4.86%, which changed the moving average for the period of 200-days by -40.20% in comparison to the 20-day moving average, which settled at $5.79. In addition, Phathom Pharmaceuticals Inc saw -24.50% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHAT starting from Henderson Molly, who sale 6,583 shares at the price of $6.59 back on Jan 21 ’25. After this action, Henderson Molly now owns 93,546 shares of Phathom Pharmaceuticals Inc, valued at $43,371 using the latest closing price.
Nabulsi Azmi, the Chief Operating Officer of Phathom Pharmaceuticals Inc, sale 7,886 shares at $6.59 during a trade that took place back on Jan 21 ’25, which means that Nabulsi Azmi is holding 233,390 shares at $51,957 based on the most recent closing price.
Stock Fundamentals for PHAT
Current profitability levels for the company are sitting at:
- -10.96 for the present operating margin
- 0.85 for the gross margin
The net margin for Phathom Pharmaceuticals Inc stands at -12.92. The total capital return value is set at -0.89.
Based on Phathom Pharmaceuticals Inc (PHAT), the company’s capital structure generated -16.48 points at debt to capital in total, while cash flow to debt ratio is standing at -1.4. The debt to equity ratio resting at -0.94. The interest coverage ratio of the stock is -4.33.
Currently, EBITDA for the company is -159.05 million with net debt to EBITDA at 0.57. When we switch over and look at the enterprise to sales, we see a ratio of 9.67. The receivables turnover for the company is 1.25for trailing twelve months and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.73.
Conclusion
To put it simply, Phathom Pharmaceuticals Inc (PHAT) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
